KR20010079701A - 알렌드로네이트 나트륨의 신규한 수화형, 이것의 제조방법 및 이것의 약학 조성물 - Google Patents

알렌드로네이트 나트륨의 신규한 수화형, 이것의 제조방법 및 이것의 약학 조성물 Download PDF

Info

Publication number
KR20010079701A
KR20010079701A KR1020017002535A KR20017002535A KR20010079701A KR 20010079701 A KR20010079701 A KR 20010079701A KR 1020017002535 A KR1020017002535 A KR 1020017002535A KR 20017002535 A KR20017002535 A KR 20017002535A KR 20010079701 A KR20010079701 A KR 20010079701A
Authority
KR
South Korea
Prior art keywords
compound
hydroxybutylidene
amino
bisphosphonic acid
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020017002535A
Other languages
English (en)
Korean (ko)
Inventor
핀켈슈타인니나
리도-하다스라미
아론힘주디스
Original Assignee
추후보정
테바 파마슈티컬 인더스트리즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 추후보정, 테바 파마슈티컬 인더스트리즈 리미티드 filed Critical 추후보정
Publication of KR20010079701A publication Critical patent/KR20010079701A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020017002535A 1998-08-27 1999-08-27 알렌드로네이트 나트륨의 신규한 수화형, 이것의 제조방법 및 이것의 약학 조성물 Ceased KR20010079701A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US9831398P 1998-08-27 1998-08-27
US60/098,313 1998-08-27
US12974399P 1999-04-16 1999-04-16
US60/129,743 1999-04-16
US14446199P 1999-07-19 1999-07-19
US60/144,461 1999-07-19
PCT/US1999/019838 WO2000012517A1 (en) 1998-08-27 1999-08-27 Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020077004456A Division KR20070034132A (ko) 1998-08-27 1999-08-27 알렌드로네이트 나트륨의 신규 수화물 형태, 이의 제조방법 및 이의 약학 조성물

Publications (1)

Publication Number Publication Date
KR20010079701A true KR20010079701A (ko) 2001-08-22

Family

ID=27378576

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020017002535A Ceased KR20010079701A (ko) 1998-08-27 1999-08-27 알렌드로네이트 나트륨의 신규한 수화형, 이것의 제조방법 및 이것의 약학 조성물
KR1020077004456A Ceased KR20070034132A (ko) 1998-08-27 1999-08-27 알렌드로네이트 나트륨의 신규 수화물 형태, 이의 제조방법 및 이의 약학 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020077004456A Ceased KR20070034132A (ko) 1998-08-27 1999-08-27 알렌드로네이트 나트륨의 신규 수화물 형태, 이의 제조방법 및 이의 약학 조성물

Country Status (30)

Country Link
US (2) US6281381B1 (enExample)
EP (1) EP1107974B1 (enExample)
JP (2) JP2002523514A (enExample)
KR (2) KR20010079701A (enExample)
AT (1) ATE334993T1 (enExample)
AU (1) AU5698899A (enExample)
BG (1) BG65329B1 (enExample)
BR (1) BR9913472A (enExample)
CA (1) CA2341459A1 (enExample)
CZ (1) CZ2001629A3 (enExample)
DE (1) DE69932620T2 (enExample)
DK (1) DK1107974T3 (enExample)
EA (1) EA002739B1 (enExample)
EE (1) EE04552B1 (enExample)
ES (1) ES2270613T3 (enExample)
HR (1) HRP20010129A2 (enExample)
HU (1) HUP0203078A3 (enExample)
IL (1) IL141423A (enExample)
IS (1) IS5864A (enExample)
LT (1) LT4888B (enExample)
LV (1) LV12720B (enExample)
NO (1) NO20010957L (enExample)
NZ (1) NZ510682A (enExample)
PL (1) PL346347A1 (enExample)
PT (1) PT1107974E (enExample)
RO (1) RO122854B1 (enExample)
SI (1) SI20581B (enExample)
SK (1) SK2482001A3 (enExample)
WO (1) WO2000012517A1 (enExample)
YU (1) YU14701A (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE455121T1 (de) * 2001-07-16 2010-01-15 Univ Paris 13 Herstellungsverfahren von derivate von bisphosphonaten
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
WO2003057136A2 (en) * 2001-12-24 2003-07-17 Teva Pharmaceutical Industries Ltd. Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
ITMI20020146A1 (it) * 2002-01-29 2003-07-29 Lyogen Ltd Alendronato monosodico amorfo e processo per la sua preparazione
US20050176685A1 (en) * 2002-04-05 2005-08-11 Daifotis Anastasia G. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20080249068A1 (en) * 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
US20050113343A1 (en) * 2003-10-14 2005-05-26 Pliva - Research And Development Ltd. Solid-state form of alendronate sodium and preparation thereof
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
PT1753395E (pt) 2004-05-24 2010-10-21 Warner Chilcott Co Llc Forma entérica sólida de dosagem oral de um bisfosfonato contendo um agente quelante
CZ296937B6 (cs) * 2004-09-02 2006-07-12 Zentiva, A. S Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
DE602005016292D1 (de) * 2004-10-29 2009-10-08 Sandoz Ag Verfahren zur herstellung von glatiramer
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
CZ297262B6 (cs) * 2004-12-28 2006-10-11 Zentiva, A. S. Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
US8003820B2 (en) * 2005-10-20 2011-08-23 Dr. Reddy's Laboratories Limited Process for preparing bisphosphonic acids
AR058168A1 (es) * 2005-11-07 2008-01-23 Merck & Co Inc Sintesis del alendronato de sodio trihidratado
NZ598071A (en) * 2006-10-27 2013-08-30 Signal Pharm Llc Uses of and pharmaceutical compositions comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds
ES2392890T3 (es) * 2006-11-22 2012-12-14 Eisai R&D Management Co., Ltd. Sal sódica de un compuesto disacarídico, procedimiento para la producción de la misma y uso de la misma
US20090076144A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bazedoxifene
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090170815A1 (en) * 2007-12-28 2009-07-02 Roxane Laboratories Incorporated. Alendronate oral liquid formulations
WO2011054182A1 (zh) * 2009-11-03 2011-05-12 Liu Li 丹参酮ⅱa磺酸钠水合物及其制备方法和用途
TWI846166B (zh) 2013-11-15 2024-06-21 美商阿克比治療有限公司 {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3434667A1 (de) * 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) * 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
US4711800A (en) * 1985-06-06 1987-12-08 Divincenzo Maureen Needlecraft with metallic substrate
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5159108A (en) * 1990-09-18 1992-10-27 Merck & Co., Inc. Process for preparing an antihypercalcemic agent
US5039819A (en) * 1990-09-18 1991-08-13 Merck & Co., Inc. Diphosphonate intermediate for preparing an antihypercalcemic agent
ATE289199T1 (de) * 1995-06-06 2005-03-15 Merck & Co Inc Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten
EP0837863A4 (en) 1995-06-06 1999-06-16 Merck & Co Inc DISODIUM ALENDRONATE PREPARATIONS

Also Published As

Publication number Publication date
WO2000012517A1 (en) 2000-03-09
EE200100126A (et) 2002-06-17
SI20581A (sl) 2001-12-31
IL141423A (en) 2005-09-25
WO2000012517A9 (en) 2000-07-13
US6281381B1 (en) 2001-08-28
JP2002523514A (ja) 2002-07-30
YU14701A (sh) 2003-01-31
KR20070034132A (ko) 2007-03-27
LT2001016A (en) 2001-10-25
LT4888B (lt) 2002-02-25
CZ2001629A3 (cs) 2001-08-15
EE04552B1 (et) 2005-10-17
EP1107974A1 (en) 2001-06-20
EP1107974B1 (en) 2006-08-02
HUP0203078A3 (en) 2005-01-28
RO122854B1 (ro) 2010-03-30
CA2341459A1 (en) 2000-03-09
PL346347A1 (en) 2002-02-11
DE69932620T2 (de) 2006-12-14
EP1107974A4 (en) 2001-09-26
AU5698899A (en) 2000-03-21
NO20010957D0 (no) 2001-02-26
ATE334993T1 (de) 2006-08-15
LV12720B (en) 2002-02-20
US20030065214A1 (en) 2003-04-03
EA002739B1 (ru) 2002-08-29
BG65329B1 (bg) 2008-02-29
PT1107974E (pt) 2006-10-31
US6696601B2 (en) 2004-02-24
HUP0203078A2 (hu) 2003-01-28
DE69932620D1 (de) 2006-09-14
SI20581B (sl) 2008-06-30
LV12720A (lv) 2001-09-20
IS5864A (is) 2001-02-26
EA200100184A1 (ru) 2001-10-22
HRP20010129A2 (en) 2005-04-30
NZ510682A (en) 2003-09-26
BR9913472A (pt) 2002-03-05
SK2482001A3 (en) 2002-01-07
ES2270613T3 (es) 2007-04-01
IL141423A0 (en) 2002-03-10
JP2009143955A (ja) 2009-07-02
BG105292A (en) 2001-12-29
DK1107974T3 (da) 2006-10-30
NO20010957L (no) 2001-04-26

Similar Documents

Publication Publication Date Title
KR20010079701A (ko) 알렌드로네이트 나트륨의 신규한 수화형, 이것의 제조방법 및 이것의 약학 조성물
US6963008B2 (en) Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
EP1702924A2 (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
US6534674B2 (en) Crystalline disodium pamidronate hydrate and process for preparing it
MXPA01002017A (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
AU2004202301B2 (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
US20090149427A1 (en) Pharmaceutically acceptable salts and hydrates of risedronic acid
EP0548834B1 (en) Stable hexahydrate of etoposide 4'-phosphate disodium salt
WO2006129056A2 (en) Process and novel salt
EP2018392A1 (en) Pharmaceutically acceptable salts and polymorphic forms
JPH05194575A (ja) 結晶性エトポシド４’−ホスフェートジエタノレート
CZ20041249A3 (cs) Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

A107 Divisional application of patent
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial

St.27 status event code: N-3-6-B10-B17-rex-PB0601

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20070124

Effective date: 20071022

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20071022

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2001 7002535

Appeal request date: 20070124

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2007101000860

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000